Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

e patients, 212 were on glimepiride alone (106 each on JANUVIA or placebo), and 229 on glimepiride and metformin (116 on JANUVIA, 113 on placebo). The primary endpoint was A1C change from baseline for the entire cohort.

The addition of JANUVIA to a sulfonylurea with or without metformin was generally well-tolerated in this study. A higher incidence of overall adverse experiences (60 vs. 47 percent) and drug-related adverse experiences (15 vs. 7 percent) were reported with JANUVIA compared to placebo in patients treated with glimepiride with or without metformin. These higher rates were partly related to a higher incidence of hypoglycemia with JANUVIA compared to placebo (12 vs. 2 percent, respectively). The higher rate of hypoglycemia has commonly been seen when antihyperglycemic agents are used in combination with sulfonylurea agents. After 24 weeks, body weight was increased more with JANUVIA than with placebo (mean change from baseline of +0.8 vs. -0.4 kg, respectively; p less than 0.001).

"These new potential uses of sitagliptin as add-on to sulfonylurea, as add-on to sulfonylurea plus metformin, and as initial therapy in combination with metformin, if approved by the FDA, would provide physicians with additional treatment options for patients with type 2 diabetes," said Mark Kipnes, M.D., associate medical director, Diabetes and Glandular Research Associates, and clinical professor of Medicine, University of Texas Health Science Center at San Antonio.

As Merck announced in February, these data have been submitted to the U.S. Food and Drug Administration (FDA) in support of proposed new indications for the use of JANUVIA. One sNDA is filed in support of a proposed new indication for the use of JANUVIA, as an adjunct to diet and exercise, in combination with metformin as initial therapy to improve glycemic control. The other sNDA is filed in support of two proposed new indications for use of JANUVIA, as an adjunct to diet and exercise, as add
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:5/21/2013)... BURLINGTON, Mass. , May 21, 2013 ... leading research and advisory firms for pharmaceutical ... of an emerging agent on key efficacy ... disease progression, has the most influence over ... for advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast ...
(Date:5/21/2013)... CLARA, Calif. , May 21, 2013 ... game-changing embedded-ultrasound platform, today announced the introduction ... that allows complete network-based communications with all ... its latest embedded-ultrasound technology, including this new ... Sao Paulo, Brazil from ...
(Date:5/21/2013)... 21, 2013  The North Shore-LIJ Health System is ... hand-washing compliance at North Shore University Hospital in ... operating rooms at Forest Hills ... The new pilot program strengthens patient safety by ... (ORs), the first time in the US that remote ...
Breaking Medicine Technology:Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 2North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 3North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 4
... June 1, 2011 Mirixa Corporation is pleased to ... licensing agreement for MirixaEdge(SM), a clinical application that supports ... Medication Therapy Management (MTM). Family Physicians Group (FPG), ... Source Pharmacy and selected it as FPG,s preferred pharmacy ...
... YORK, June 1, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0305172/Global-Intravenous-IV-Iron-Drugs-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... Intravenous (IV) Iron Drugs in US$ Million. ...
Cached Medicine Technology:MirixaEdge(SM) to be Licensed by One Source Pharmacy, LLC 2MirixaEdge(SM) to be Licensed by One Source Pharmacy, LLC 3Global Intravenous (IV) Iron Drugs Industry 2Global Intravenous (IV) Iron Drugs Industry 3Global Intravenous (IV) Iron Drugs Industry 4Global Intravenous (IV) Iron Drugs Industry 5Global Intravenous (IV) Iron Drugs Industry 6Global Intravenous (IV) Iron Drugs Industry 7
(Date:5/21/2013)... Residents in St. Petersburg, FL have a new ... David Sherberg, DMD, has joined Coast Dental Pasadena, located ... preventive, restorative and cosmetic dentistry to patients age 12 ... a wide variety of services including teeth ... bridges, dentures, dental implant restorations, veneers, laser therapy, oral ...
(Date:5/21/2013)... 21, 2013 Three major Ohio universities and four ... to establish a new collaborative research program aimed exclusively ... March of Dimes intends to invest $10 million in ... of Dimes Prematurity Research Center -- Ohio Collaborative is ... President of the March of Dimes. "This new transdisciplinary, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Healthcare industry ... at the premier “Start Me Up” Emerging Healthcare Technology ... Education in Madison, Wisconsin. This new event is ... a gathering of national healthcare leaders being held June ... the University of Wisconsin. , Funding for healthcare information ...
(Date:5/21/2013)... Austin, TX (PRWEB) May 21, 2013 It’s ... off to summer camp or starting practice for summer or ... required before camp or sporting activities can begin. , ... an affordable option for youth sports or camp physicals ... MedSpring’s on-site doctors will review a child’s medical history, perform ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Everspark Interactive, ... firms, has been growing rapidly over the past year ... was hired to spearhead interactive marketing efforts for Kids ... , Everspark started as a local effort, specializing ... guiding search traffic to a company's website. The company ...
Breaking Medicine News(10 mins):Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 3Health News:New multi-million dollar research center aims to solve the mystery of premature birth 2Health News:New multi-million dollar research center aims to solve the mystery of premature birth 3Health News:“Start Me Up" Healthcare Conference: Where Healthcare CIOs, Entrepreneurs and Investors Meet 2Health News:MedSpring Offers Camp and Sports Physicals For $29 2Health News:Everspark Named Interactive Marketing Company for Kids II 2
... ward off obesity as children get older.// The ... data available on breastfeeding and weight of children ... at clarifying the situation. In both, investigators followed ... see how breastfeeding impacts weight. Detailed breastfeeding histories ...
... the rejection of being picked last for a sports team, ... or being turned down for a date. //Whatever the social ... in our heads. ,According to researchers, the brain seems ... same way ,as physical pain. To study this phenomenon, investigators ...
... for cancer complain of feeling weak //and tried, and ... symptoms. A new study suggests that may not be ... with worse prognosis after radiotherapy, the doctors assumed the ... of the therapy, as well., ,Not so, report ...
... complain of feeling weak and tired,// and doctors often ... new study suggests that may not be a good ... prognosis after radiotherapy, the doctors assumed the treatment would ... therapy, as well., ,Not so, report German researchers ...
... took the drug earlier than suggested may have done migraine ... the medication works best when taken at the first sign ... severe, as was the requirement of the original study., ... agonists for the treatment of migraine have required patients to ...
... shows drug-emitting stents are effective at keeping arteries open in ... coated with the drug sirolimus. It is an immunosuppressive agent. ... the artery from closing again.// ,Stents are used to ... very useful. However, in 30 percent of patients with diabetes, ...
Cached Medicine News:Health News:Pain of Denial Compared to Physical Pain 2
Open blade design with aspiration capabilities for removing fluids from the operative site....
Pediatric model. Spring-controlled spread of blades with locking mechanism. Dull finish. Blades: 11 mm....
Fenestrated blades with screw-controlled spread. Dull finish. Blades: 15 mm....
Replacement snares for the E3525. 3 per package....
Medicine Products: